Teva’s subcutaneous asthma drug fails in PhIII
Teva’s quest to expand approval of its respiratory drug Cinquair/Cinqaero with a new mode of delivery has hit a snag, after two late-stage studies failed to hit their targets.
Read More
Tag: reslizumab
Scotland approves three new meds for NHS use
The Scottish Medicines Consortium (SMC) has published new advice accepting three new medicines for use by NHS Scotland, offering patients new treatment options for soft tissue sarcoma, acromegaly and hepatitis C
Read More
NICE u-turn backs use of Teva’s asthma biologic
The National Institute for Health and Care Excellence (NICE) is now backing routine NHS commissioning of Teva’s Cinqaero to treat a severe form of asthma after having initially been minded to block the drug’s use.
Read More
NICE minded not to recommend Teva’s asthma biologic
Cost regulators for technologies funded by the NHS in England and Wales say they currently are minded not to recommend routine use of Teva’s asthma biologic Cinqaero.
Read More
EU nod for Teva’s asthma biologic
The European Commission has issued a green light for Teva’s Cinqaero in the 28 countries of the European Union in addition to Norway, Liechtenstein and Iceland.
Read More
Six new medicines put forward for EU nod
Six new medicines have cleared a key hurdle on the path to European approval after winning favour with regulatory advisors.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
